cyrilzakka/clinical-trials huggingface dataset:
Split Renal Function Using 99mTc-DTPA Versus 99mTc-DMSA in Kidney Patients of Wide Age Ranges.

To evaluate split renal function using Tc-99m DTPA versus Tc-99m DMSA.

Split renal function (SPR) is a determination of the relative contribution of each of the two kidneys . It gives a useful information in several conditions such as evaluating unilateral renal disorders, assessing individual kidney function before and after intervention, and before live donor nephrectomy. Different radiopharmaceuticals such as technetium-99m dimercaptosuccinic acid (99mTc-DMSA), technetium-99m diethylenetriaminepentaaceticacid (99mTc-DTPA), technetium-99m mercaptoacetyltriglycine (99mTc-MAG3), Iodine 131 orthoiodohippurate and more recently technetium-99 m ethylenedicysteine (99mTc-EC) were used, However, 99mTc-DMSA as a static renal agent is considered the most reliable method to measure relative renal function and the most appropriate tracer for renal cortical imaging . In some papers, it is emphasized that relative renal function calculated with 99mTc-DTPA is as reliable as 99mTc-DMSA .‬ The investigators design the study to evaluate the difference in estimation of split renal function using the available two radiopharmaceuticals: Tc-99m DTPA and Tc-99m DMSA.

Eligibility Criteria:
Inclusion Criteria:

1. Kidney patients of wide age ranges.
2. Patients with renal disorders who referred for DMSA and DTPA split renal function.
3. Patients able to sleep in a fixed position for 20 minutes.

Exclusion Criteria:

1. Children unable to sit calm without movement during imaging.
2. Severely ill patients.
3. Patients with allergy to one or more of material method.
Patient Observational Pain and Activity Survey (POPAS) Study Using RS-4i Sequential Stimulator with Intersperse Technology in Axial Spine and Peripheral Joint Pain

Spine pain and joint pain are among the most common worldwide ailments and directly contributes to disability as well as increased duration of care. Spine and joint pain affect work sick leave, production and increased financial costs to healthcare. Non-invasive treatments for spine and joint pain can vary widely from lifestyle changes, physical therapy, oral medication, and select medical devices, that can improve pain level and help improve the quality of life of individuals. Thus, the general population suffers from an ailment that has multiple conservative treatment options with variable outcomes.

Transcutaneous Electrical Neuromuscular Stimulation (TENS) has been show to decrease pain and restore function. Interferential therapy (INF) is a specific signal type that is effective for reducing musculoskeletal pain. Neuromuscular Electrical Stimulation (NMES) uses a specific signal type to cause muscles to contract and therefore provide functional improvement. The RS-4i Plus is an FDA-regulated prescription TENS medical device that outputs an INF signal and a NMES signal, and a unique Intersperse signal, which combines NMES and INF into a single treatment. Therefore, the goal of this study is to determine if use of the prescribed RS-4i Plus in patients presenting with pain, axial or peripheral joint, can be efficacious in decreasing the patient's pain and improving their activity measured at one month, three months, and six months of use.


Eligibility Criteria:
Inclusion Criteria:

1. chronic and persistent MSK lumbar back pain for greater than 12 weeks as documented in patient records
2. Age 18 to 89
3. Willingness to comply with study protocol
4. Signed Patient Consent on file
5. Verified patient usage collected from RS-4i Plus via patient data adapter

Exclusion Criteria:

1. Pregnancy
2. Any contraindications, as indicated in the RS-4i Plus prescribing information
3. Substantial allergy to adhesives
4. Skin infection or irritation of skin where electrodes are to be placed
5. Pacemaker/ICD
6. Abnormal skin sensation
7. Serious psychological disorder
8. End-stage cardiac, peripheral arterial or pulmonary disease
9. h/o recent vertebral fracture
10. Severe degenerative or traumatic neuromuscular disease
11. Non-English speaking
12. Uncontrolled diabetes meelitus (Hb A1c\> 8.5%)
13. ESRD or ESHD
14. Active cancer
CT Findings in Surgically Treated Focal Pancreatic Disease- A Retrospective Study

To retrospectively investigate CT imaging features of autoimmune and chronic pancreatitis (AIP and CP) mimicking pancreatic ductal adenocarcinoma in surgically resected patients.


Eligibility Criteria:
Inclusion Criteria:

* Definite diagnosis of autoimmune pancreatits or adenocarcinoma

Exclusion Criteria:

* No surgery
Comparison of Non-invasive and Invasive Blood Pressure Monitors

To compare a noninvasive and continuous radial artery blood pressure measurements utilizing ViTrack (developed by Dynocardia) to the standard of care radial artery catheterization, in patients undergoing surgery or those who are being cared for in the intensive care unit

The ViTrack is strapped over the radial artery at the wrist.The ViTrack blood pressure cuff will be utilized to obtain continuous blood pressure (BP) readings throughout the surgical procedure or intensive care unit. This will allow us to compare BP readings between the non-invasive ViTrack device and the standard of care invasive intra-arterial catheters readings. Data collection from both the ViTrack and arterial catheter occur in the opposite wrists.

Eligibility Criteria:
Inclusion Criteria:

* Patients between the ages of 18 - 90 years age who are undergoing any surgery or in the intensive care unit and require intra-arterial catheterization for continuous BP measurement.
* Patients having elective surgeries.
* Patients having emergent surgeries, but only if research staff can have appropriate time to review study with patient and obtain signature on fact sheet prior to administration of medications that could affect coherency.
* Patients who are able to review, verbalize understanding, and sign fact sheet. If patient has a health care proxy (HCP) or legal guardian, study will be reviewed, and signature of HCP or legal guardian will be obtained.

Exclusion Criteria:

* Inability to obtain consent from the patient, HCP or legal guardian
* Greater than 10% difference in BP measurements between both arms prior to surgery
* Pregnant women
* Prisoners
* Inability to insert a radial artery catheter
* Any other condition that would increase the risk of participation in the study in the opinion of the site Investigator
* Upper extremity arteriovenous haemodialysis shunt
* Upper extremity amputation
* Surgical position/draping precludes access to the wrist.
* Wrist distortion or pain from arthritis
* Prior trauma or surgery at the radial artery monitoring site
Evaluation of Reflex Tear Production

The purpose of this study is to evaluate reflex tear production following cotton swab nasal stimulation in subjects with dry eye disease (DED).

The primary analysis will assess the change from baseline (pre- versus immediately post-cotton swab nasal stimulation) in tear meniscus height (TMH) using optical coherence tomography (OCT). This study will consist of one visit on a single day.

Eligibility Criteria:
Key Inclusion Criteria:

* Within the last 12 months, have a previous history of dry eye disease, either clinician diagnosed or patient reported.
* Within the last 6 months, have used, or desired to use artificial tears for dry eye symptoms.
* Corrected Visual Acuity (Snellen) 20/200 or better in both eyes.
* Good general and ocular health, as determined by the investigator using medical history, ophthalmic examination and history.
* Able, as assessed by the investigator, and willing to follow study instructions.
* Other protocol-specified inclusion criteria may apply.

Key Exclusion Criteria:

* Current evidence of any clinically significant ophthalmic disease other than dry eye (for example, glaucoma or macular degeneration).
* Use of artificial tears within 2 hours of the Study Visit.
* History of ocular surgery within 1 year of the Study Visit.
* Use of contact lenses in either eye within 7 days of the Study Visit.
* Use of lid hygiene (all forms of lid care) or heat masks within 7 days of the Study Visit.
* Use of any topical ocular anti-inflammatory medications, any topical ocular corticosteroid, or any non-steroidal-anti-inflammatory agents within 30 days of the Study Visit.
* Other protocol-specified exclusion criteria may apply.
Use of Videos to Improve Patient Knowledge on Prenatal Genetics

This is a randomized controlled trial of a low income and low health literacy population of pregnant women from a diverse racial and ethnic background to assess the effectiveness of a pre-visit educational video on prenatal genetic screening and testing options.

During pregnancy, women are routinely counseled about the risks of their offspring to have a chromosomal abnormality or birth defects. Both prenatal screening and diagnostic testing options to exclude aneuploidy should be offered to all pregnant women early in their pregnancy. A standardized educational video on prenatal screening may enhance a patient's understanding and knowledge of testing and support more informed decisions.

The objective of this study is to evaluate and compare patient knowledge scores on prenatal genetic screening before and after a standard prenatal care visit compared to the addition of a pre-appointment educational video.

Eligibility Criteria:
Inclusion Criteria:

* pregnancy, english or spanish-speaking

Exclusion Criteria:

* minors \<18 years old,
* \> 21 completed weeks of gestational age,
* prior genetic counseling during current pregnancy
* fetus with known ultrasound abnormality
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>/=18 years of age
* Histologically confirmed advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) with locally advanced and/or metastatic disease
* HER2-positive tumor
* Patients who are eligible for treatment with Herceptin according to the judgment of the physician

Exclusion Criteria:

* Unwilling or unable to sign informed consent form
* Any contraindications, interactions and incompatibilities to Herceptin
Investigation of the Relationship Between the Use of Social Media and Functional Level in Children With CP

The aim of this study is to examine the relationship between screen usage time and problematic social media use in children with Cerebral Palsy (CP) with motor function, hand function, speech and vision function.

Problematic Media Use Measure, Strengths and Difficulties Questionnaire were administered to 158 parents of children with CP. In order to determine the screen usage time, parents were asked about the screen usage time of their children on weekdays and weekends, and the average usage time in a week was calculated. Gross Motor Function Classification System (GMFCS), Manual Abilities Classification System (MACS), Eating and Drinking Ability Classification System (EDACS), Communication Function Classification System (CFCS),and Visual Function Classification System (VFCS) were used to determine functional levels.The structural equation model was used for statistical analysis.

Eligibility Criteria:
Inclusion Criteria:

* Parents of children with CP aged 4-18 years
* Parents of children with CP without severe cognitive problems, being a primary caregiver.

Exclusion Criteria:

* Not being a primary caregiver
Biologic Therapy for Generalized Pustular Psoriasis

The investigators aim to compare the efficacy and safety of secukinumab and ustekinumab in patients with generalized pustular psoriasis (GPP), and to explore the impact of genetic mutation types on clinical efficacy. The main questions the study aims to answer are:

Is there a difference in the effectiveness of secukinumab and ustekinumab in the treatment of GPP? How is the safety of secukinumab and ustekinumab in the treatment of GPP? Does the type of genetic mutation in GPP patients affect the efficacy of secukinumab and ustekinumab? The investigators will compare patients treated with secukinumab to those treated with ustekinumab to see the difference in the effectiveness of the two drugs in treating GPP.

Participants will:

The investigators conducted a 48-week follow-up study on 65 participants who were admitted to the dermatology department of the First Affiliated Hospital of Fujian Medical University for GPP from July 2019 to December 2022. All participants underwent saliva-based genetic testing.

Efficacy analyses were performed based on the scores of Generalized Pustular Psoriasis Area and Severity Index (GPPASI) and Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) at week 0, 2, 4, 12, 24, and 48.

Participants were also asked to report all adverse events (AEs) during follow-up.


Eligibility Criteria:
Inclusion Criteria:

1. Patients meet the diagnostic criteria for GPP.
2. Patients had an average GPPGA score of 3 or higher (moderate to severe disease).
3. Patients had discontinued the treatment with non-biologic agents before they started the treatment with ustekinumab/secukinumab.

Exclusion Criteria:

1. Pregnant and lactating patients.
2. Patients with malignant tumors.
3. Patients with a history of multiple drug allergies or a severe allergic constitution.
4. Contraindications for ustekinumab/secukinumab, including active tuberculosis, active hepatitis B, hepatitis C, or inflammatory bowel disease.

Patients who were severely immunocompromised.
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

This study will evaluate the safety and efficacy of BOTOX® in the treatment of adult post-stroke lower limb spasticity.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of post-stroke lower limb spasticity for at least 3 months
* Minimum body weight of 50 kg
* Never treated with botulinum toxin of any serotype for any reason, or if previously treated with botulinum toxin of any serotype, if previously treated for spasticity in the affected lower limb, must have been administered

  * 20 weeks before Day 1, or if previously treated for any other indication must have been administered ≥12 weeks prior to Day 1

Exclusion Criteria:

* Spasticity in the opposite leg that requires treatment
* Casting of the study limb within 6 months or planned casting during the first 12 weeks of the study
* Treatment modalities in the study limb including ultrasound, electrical nerve stimulation, electrical stimulation, acupuncture within 1 month of Day 1 or treatments planned during the study
* Not able to perform 10 meter walking test independently with or without assistive device
* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
Accelerated Brain Volume Loss in People With Multiple Sclerosis

To explore whether brain volume loss (BVL) in people with multiple sclerosis (MS), assessed on magnetic imaging (MRI) data obtained during routine medical follow-up (and thus outside a standardized research environment), differs from that of healthy controls and correlates with measures of physical and/or cognitive disability, the latter also gathered during regular clinical practice.

This project will not be the first study on real-world data in an existing MS cohort. A NMSC research group has already reported on the contribution of a single brain volumetric assessment to the prediction of MS-related disability10 - with distinct patterns for the Expanded Disability Status Scale (EDSS) as a measure of physical disability11, and Symbol Digit Modalities Test (SDMT) as a measure of cognitive disability12 - and found a threshold effect for the lowest brain volumes with regard to SDMT worsening over time10. Ghione and co-workers, in turn, have demonstrated a positive correlation between annualized BVL and EDSS progression based on the EDSS in a very large sample containing nearly 2,000 individuals13. The novelty of this new study lies in the fact that the investigators want to explore the correlations between BVL and changes in an expanded set of routinely collected clinical variables in our center - in addition to the EDSS score - such as Timed 25-Feet Walk Test (T25FWT)14, 9-Hole Peg Test (9HPT)15 and SDMT.

Eligibility Criteria:
Inclusion Criteria:

* MRI and volumetry performed minimum 48 and maximum 60 months apart

Exclusion Criteria:

* none
Effects of Joint Effusion on Quadriceps Muscle

The present study investigated whether the presence of fluid in the joint affected peak torque and the root mean square (RMS) values of surface electromyography (EMG) in patients symptomatic for osteoarthritis (OA).

Several studies have shown that knee effusion influenced quadriceps muscle activity and induced quadriceps arthrogenic muscle inhibition in normal volunteers. However, the effect of joint effusion on the quadriceps of patients with OA is controversial,and few patients with OA have been included in studies of joint effusion.

Eligibility Criteria:
Inclusion Criteria:

* 50 years old or older with knee osteoarthritis
* knee pain without joint effusion confirmed by ultrasonography

Exclusion Criteria:

* the presence of knee joint effusion determined using US
* a history of knee injury or surgery
* a history of knee injection within 3 months
* a history of inflammatory arthritis
* taking anticoagulants
* balance or gait disturbance
* diabetes mellitus
The Effect of Multidomain Dietary Education in Type 2 Diabetic Adults

The goal of this clinical trial is to \[learn about cognitive stimulation by multidomain dietary education including the dietary board game via LINE in non-dementic type 2 diabetic adults. The main questions it aims to answer are:

\[Question 1: Could multi-domain dietary education as cognitive stimulation improve cognitive function?\] \[Question 2: Could multi-domain dietary education improve dietary control belief ?\] \[Question 3: Could multi-domain dietary education improve health behavior?\] \[Question 4\]: Could multi-domain dietary education improve HbA1C, and lipid profile? Participants of experimental A group will receive a video about lifestyle education 5 minutes weekly for 3 weeks, a dietary board game 10 minutes weekly for 10 weeks, and a 24-hour dietary recall record 2 times weekly for 7 weeks. And participants of the experimental B group receive the usual clinical treatment. Then experimental A and Experimental B groups will cross over 12 weeks later.

Researchers will compare the effect of intervention between the experimental A group and the experimental B group.

Cognitive function was measured by the Saint Louis University Mental State (SLUMS) score. And we exclude the dementia group according to the SLUMS definition (\<21 if the participants graduated from senior high school or above, \<20 if the education level below senior high school).

Experimental group A received 10-week curriculum from 1st week to 10th week, and receive d usual clinical care from 13th week to 22th week. Experimental B group received usual clinical care from 1st week to 10th week, and received 10-week curriculum from 13th week to 22th week.

Eligibility Criteria:
Inclusion Criteria:

* The onset age of Diabetes Mellitus is more than 20 years old
* Diagnosis of Diabetes according to past history including type 2 diabetes mellitus or drug history including oral anti-diabetic drugs

Exclusion Criteria:

* SLUMS meets the Dementia definition.
* HbA1C ≥ 10.0%
* Rejected our study.
* History of stroke.
* History of depression.
* History of psychiatric disease.
* Visual impairment.
* Hearing impairment.
* Can't understand the informed consent
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia

This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in stage III-IV chronic kidney disease patients not on dialysis receiving Mircera for the treatment of chronic renal anemia. Eligible patients will be followed for 24 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, 18 to 65 years of age, inclusive
* Patients with stage III-IV chronic kidney disease not on dialysis
* Erythropoiesis stimulating agent (ESA) naïve with Hb \< 10 g/dL, or on treatment with ESAs other than Mircera and Hb within the target range of 10-12 g/dL
* Adequate iron status as judged by the treating physician

Exclusion Criteria:

* Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication
* Clinically significant concomitant disease or disorder as defined by protocol
* Clinical suspicion of pure red cell aplasia (PRCA)
* Planned elective surgery during the study period , except for cataract surgery or vascular access surgery
* Transfusion of red blood cells in the previous 2 months
* Pregnant women
* Contraindications for Mircera according to local prescribing information or as judged by the investigator
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects


Eligibility Criteria:
Inclusion Criteria:

1. Healthy elderly subjects ≥65 years,
2. Individuals willing to provide written informed consent,
3. Individuals in good health,
4. Individuals willing to allow for their serum samples to be stored beyond the study period.

Exclusion Criteria:

1. Individuals not able to understand and follow study procedures,
2. History of any significant illness,
3. History of any serious chronic medical condition or progressive disease,
4. Presence of medically significant cancer,
5. Known or suspected impairment/alteration of immune function,
6. Presence of any progressive or severe neurologic disorder,
7. Presence of any bleeding disorders or conditions that prolongs bleeding time,
8. History of allergy to vaccine components,
9. Receipt of any other investigational product within 30 days prior to entry into the study,
10. History of previous H5N1 vaccination,
11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,
12. Receipt of any other vaccine within 2 weeks prior to entry into the study
13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended study vaccination,
14. Body mass index (BMI) ≥ 35 kg/m2,
15. History of drug or alcohol abuse,
16. Any planned surgery during study period,
17. Individuals conducting the study and their immediate family members,
18. Individuals with behavioral or cognitive impairment or psychiatric diseases.